Evidence map›Paper›PMID 34453498›Full record

Trial reportAnnals of clinical and translational neurology2021

Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy.

Charlotte Lilien, Harmen Reyngoudt, Andreea Mihaela Seferian, Teresa Gidaro, Mélanie Annoussamy, Virginie Chê, Valérie Decostre, Isabelle Ledoux, Julien Le Louër, Eric Guemas and 5 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Annals of clinical and translational neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Charlotte LilienInstitut de Myologie, Paris, France.
Harmen ReyngoudtInstitut de Myologie, Paris, France.ORCID 0000-0002-0777-2711
Andreea Mihaela SeferianInstitut de Myologie, Paris, France.
Teresa GidaroInstitut de Myologie, Paris, France.
Mélanie AnnoussamyInstitut de Myologie, Paris, France.
Virginie ChêInstitut de Myologie, Paris, France.
Valérie DecostreInstitut de Myologie, Paris, France.
Isabelle LedouxInstitut de Myologie, Paris, France.
Julien Le LouërInstitut de Myologie, Paris, France.
Eric GuemasBIOSSEC, Paris, France.
Francesco MuntoniDubowitz Neuromuscular Centre, University College London, Great Ormond Street Institute of Child Health, London, United Kingdom.
Jean-Yves HogrelInstitut de Myologie, Paris, France.ORCID 0000-0003-0045-7505
Pierre Georges CarlierInstitut de Myologie, Paris, France.
Laurent ServaisInstitut de Myologie, Paris, France.ORCID 0000-0001-9270-4061
PreU7 Study Group
Institut de Myologie · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRUniversity of Oxford · GBGreat Ormond Street Hospital · GBParis Biotech Santé · FRSysnav (France) · FR

Funding

Advanced Diagnostics for New Therapeutic Approaches (Institut Mérieux)Association Française contre les Myopathies (AFM)French public agency OSEOGénéthonMedical Research Council MC_PC_16082Muscular Dystrophy UKNIHR GOSH BRC
6 · The paper itself

Abstract

objectiveTo understand the natural disease upper limb progression over 3 years of ambulatory and non-ambulatory patients with Duchenne muscular dystrophy (DMD) using functional assessments and quantitative magnetic resonance imaging (MRI) and to exploratively identify prognostic factors.

methodsForty boys with DMD (22 non-ambulatory and 18 ambulatory) with deletions in dystrophin that make them eligible for exon 53-skipping therapy were included. Clinical assessments, including Brooke score, motor function measure (MFM), hand grip and key pinch strength, and upper limb distal coordination and endurance (MoviPlate), were performed every 6 months and quantitative MRI of fat fraction (FF) and lean muscle cross sectional area (flexor and extensor muscles) were performed yearly.

resultsIn the whole population, there were strong nonlinear correlations between outcome measures. In non-ambulatory patients, annual changes over the course of 3 years were detected with high sensitivity standard response mean (|SRM| ≥0.8) for quantitative MRI-based FF, hand grip and key pinch, and MFM. Boys who presented with a FF<20% and a grip strength >27% were able to bring a glass to their mouth and retained this ability in the following 3 years. Ambulatory patients with grip strength >35% of predicted value and FF <10% retained ambulation 3 years later.

interpretationWe demonstrate that continuous decline in upper limb strength, function, and MRI measured muscle structure can be reliably measured in ambulatory and non-ambulatory boys with DMD with high SRM and strong correlations between outcomes. Our results suggest that a combination of grip strength and FF can be used to predict important motor milestones.

Indexed as

Disease ProgressionMuscular Dystrophy, DuchenneUpper ExtremityAdiposityAdolescentChildDystrophinExonsGenetic TherapyHand StrengthHumansMagnetic Resonance ImagingMaleDMD protein, humanDystrophin

Identifiers

PMID34453498
PMCPMC8528463
OpenAlexW3194064329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.